jRCT2031240677招募中不适用
A Double-Blind Study of SB206 in Japanese Patients with Molluscum Contagiosum
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 500
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 2age old over 至 No limit（—）
- 性别
- All
入选标准
- •Japanese patients with molluscum contagiosum aged 2 years or older and in good general health;
- •Patients who are able to understand and follow study instructions or who have support from the parent or legal guardian;
- •Patients who have a documented informed consent from voluntary signed by subject or a representative (parent or legal guardian) who received full explanations regarding the objectives and details of the study and the study drug.
排除标准
- •Patients who have molluscum contagiosum only in periocular area;
- •Patients who have received any treatment for molluscum contagiosum during the 14 days prior to Baseline;
- •Patients who are suspected to be immunosuppressed or have immunodeficiency disorder, or are on immunosuppressive treatment;
- •Patients who have history or presence of clinically significant medical, psychiatric, or emotional condition that, in opinion of the investigator, would compromise the safety of the subject or the quality of the data.
结局指标
主要结局
-
Proportion of subjects with complete clearance of all treatable MC at Week 12.
次要结局
未报告次要终点
研究者
相似试验
未知
1 期
A Phase 1 Study of LY2606368 in Japanese Patients with Advanced Solid TumorseoplasmJPRN-jRCT2080222962Eli Lilly Japan K.K.
未知
1 期
A phase 1/2 study of E6005 in Japanese patients with atopic dermatitisAtopic dermatitsJPRN-jRCT2080221229Eisai Co., Ltd.40
已完成
2 期
Japanese phase II study in untreated patients with CD20 positive B-cell non-Hodgkin's lymphoma evaluating safety of 90-minute infusion of rituximab.CD20 positive follicular lymphoma or diffuse large B-cell lymphoma.JPRN-jRCT2080223607ZENYAKU KOGYO CO., LTD.33
终止
2 期
A Clinical Phase 2 Study of E6011 in Japanese Subjects with Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic AcidPrimary Biliary CholangitisJPRN-jRCT2080223460EA Pharma Co.,Ltd.80
未知
1 期
A Two-Part Study in Japanese Patients With Advanced or Metastatic NSCLC. Open-Label Phase I to Assess the Safety & Tolerability of AZD2171 in Combination With Pac/Carb, Then a Phase II, Randomised, Double-Blind Study to Assess the Efficacy of AZD2171 Alone and in Combination With AZD2171 and Pac/CarbCarcinoma, Non-Small-Cell LungJPRN-jRCT2080220478AstraZeneca